147

Octreotide 200mcg Injection

Part A

Prescriber Criteria: Consultant Gastroenterologist
Consultant Oncologist
Consultant Palliative Care
Consultant Surgeon

Inpatient use only:

- Extreme cases of fistulae
- Rare cases of oesophageal varices not responding to other therapy (off-license indication).

Outpatient and Inpatient use:

1. Malignant Diseases

To be used for intestinal obstruction resulting from widespread intra-abdominal malignancy.

Duration of Approval:
1 year

Part B

Prescriber Criteria: Consultant Emergency Medicine

Inpatient use only:

- Sulphonylurea-induced hypoglycaemia refractory to IV glucose

Part C

Prescriber Criteria: Consultant Endocrinology and Diabetes
Consultant Oncologist

Outpatient and Inpatient use:

1. Pituitary Adenomas
2. Malignant Diseases

Patients with:

- Pituitary adenomas/carcinomas secreting growth hormone (usually until radiotherapy has time to take effect)
- Carcinoid syndrome
- Vasoactive intestinal peptide tumours (VIPomas)
- Insulinomas
- Other hormonally active endocrine neoplasia that are shown to produce a significant response to subcutaneous octreotide such as thyrotropin secreting pituitary adenomas.

Duration of Approval:
1 month (As a test dose. Patients should then be started on LAR Octreotide as per protocol)